Work

Abstract P2-11-11: Phase II trial of exemestane with immunomodulatory oral cyclophosphamide in metastatic hormone receptor (HR)-positive breast cancer: Prolonged progression-free survival (PFS) in patients with distinct T regulatory cell (Treg) profile

Year: 2016

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs15-p2-11-11

Authors: M Kwa, Y Novik, R Oratz, K Jhaveri, J Wu, P Gu, M Meyers, F Muggia, M Bonakdar, C Abidoglu, L Kozhaya, X Li, B Joseph, A Iwano, K Friedman, JD Goldberg, D Unutmaz, S Adams

Institutions: The Jackson Laboratory for Genomic Medicine, New York University

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2407918516

Cites:

Cited by:

Related to: 10